Other equities research analysts have also recently issued reports about the stock. Analysts at Dougherty & Co downgraded shares of Accretive Health from a buy rating to a neutral rating in a research note to investors on Wednesday. They noted that the move was a valuation call. Analysts at Raymond James initiated coverage on shares of Accretive Health in a research note to investors on Wednesday, January 16th. They set a strong-buy rating and a $16.00 price target on the stock.
Four research analysts have rated the stock with a buy rating, three have given a hold rating, and one has given a sell rating to the company’s stock. Accretive Health currently has a consensus rating of overweight and a consensus price target of $13.00.
Shares of Accretive Health opened at 9.58 on Wednesday. Accretive Health has a one year low of $7.75 and a one year high of $25.30. The stock’s 50-day moving average is currently $12.48. The company has a market cap of $943.6 million and a P/E ratio of 56.35.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.